Jenner & Block Advises Theratechnologies in Acquisition Agreement
News
July 2, 2025
On July 2, Jenner & Block advised its client Theratechnologies Inc. in entering into a definitive arrangement agreement to be acquired by CB Biotechnology LLC, an affiliate of Future Pak LLC. Theratechnologies is a Quebec-based commercial-stage biopharmaceutical company focused on the commercialization of innovative therapies.
Under the terms of the agreement, Future Pak will acquire all of the issued and outstanding common shares of Theratechnologies for US $3.01 per share in cash plus one contingent value right per share for potential additional payments of up to US $1.19 per share, depending on milestone achievements. The transaction represents a total potential equity value of approximately US $254 million, with premiums of up to 216% over Theratechnologies’ closing price prior to Future Pak’s initial non-binding proposal.
“This transaction is the result of a thorough and deliberate sale process aimed at maximizing value for our shareholders,” stated Frank A. Holler, Chair of the Board of Directors of Theratechnologies. “Future Pak’s interest in acquiring Theratechnologies represents a vote of confidence in the company we’ve built, recognizing our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.”
The transaction, which is expected to close in Theratechnologies’ fourth quarter ending November 30, 2025, is subject to customary closing conditions, including shareholder and court approvals.
The deal team was led by Partner Martin Glass, and included Partners Christopher Abbott, Geoffrey Davis, Madeleine Findley, Matthew Renaud, and Emma Sullivan, and Associates Kristen Iglesias and Daniel Robertson.
Related Attorneys
Related Capabilities
Related Locations
© 2026 Jenner & Block LLP. Attorney Advertising. Jenner & Block LLP is an Illinois Limited Liability Partnership including professional corporations. This publication, presentation, or event is not intended to provide legal advice but to provide information on legal matters and/or firm news of interest to our clients and colleagues. Readers or attendees should seek specific legal advice before taking any action with respect to matters mentioned in this publication or at this event. The attorney responsible for this communication is Brent E. Kidwell, Jenner & Block LLP, 353 N. Clark Street, Chicago, IL 60654-3456. Prior results do not guarantee a similar outcome. Jenner & Block London LLP, an affiliate of Jenner & Block LLP, is a limited liability partnership established under the laws of the State of Delaware, USA and is authorised and regulated by the Solicitors Regulation Authority with SRA number 615729. Information regarding the data we collect and the rights you have over your data can be found in our Privacy Notice. For further inquiries, please contact dataprotection@jenner.com.
News
July 2, 2025
On July 2, Jenner & Block advised its client Theratechnologies Inc. in entering into a definitive arrangement agreement to be acquired by CB Biotechnology LLC, an affiliate of Future Pak LLC. Theratechnologies is a Quebec-based commercial-stage biopharmaceutical company focused on the commercialization of innovative therapies.
Under the terms of the agreement, Future Pak will acquire all of the issued and outstanding common shares of Theratechnologies for US $3.01 per share in cash plus one contingent value right per share for potential additional payments of up to US $1.19 per share, depending on milestone achievements. The transaction represents a total potential equity value of approximately US $254 million, with premiums of up to 216% over Theratechnologies’ closing price prior to Future Pak’s initial non-binding proposal.
“This transaction is the result of a thorough and deliberate sale process aimed at maximizing value for our shareholders,” stated Frank A. Holler, Chair of the Board of Directors of Theratechnologies. “Future Pak’s interest in acquiring Theratechnologies represents a vote of confidence in the company we’ve built, recognizing our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.”
The transaction, which is expected to close in Theratechnologies’ fourth quarter ending November 30, 2025, is subject to customary closing conditions, including shareholder and court approvals.
The deal team was led by Partner Martin Glass, and included Partners Christopher Abbott, Geoffrey Davis, Madeleine Findley, Matthew Renaud, and Emma Sullivan, and Associates Kristen Iglesias and Daniel Robertson.
Related Attorneys
Related Capabilities
Related Locations
© 2026 Jenner & Block LLP. Attorney Advertising. Jenner & Block LLP is an Illinois Limited Liability Partnership including professional corporations. This publication, presentation, or event is not intended to provide legal advice but to provide information on legal matters and/or firm news of interest to our clients and colleagues. Readers or attendees should seek specific legal advice before taking any action with respect to matters mentioned in this publication or at this event. The attorney responsible for this communication is Brent E. Kidwell, Jenner & Block LLP, 353 N. Clark Street, Chicago, IL 60654-3456. Prior results do not guarantee a similar outcome. Jenner & Block London LLP, an affiliate of Jenner & Block LLP, is a limited liability partnership established under the laws of the State of Delaware, USA and is authorised and regulated by the Solicitors Regulation Authority with SRA number 615729. Information regarding the data we collect and the rights you have over your data can be found in our Privacy Notice. For further inquiries, please contact dataprotection@jenner.com.
News and Insights
Event
Associate Steven Arango to Speak at the Veterans' Legal Career Fair
On September 18, Associate Steven Arango will speak on a panel at the Veterans' Legal Career Fair (VLCF), the only legal career fair in the United States dedicated to veterans, active-duty service members, and military spouses.
September 18, 2026
Event
Partner David Greenwald to Speak at PLI Program on Privilege and AI
On August 17, David Greenwald will speak at "Fitting New “Tech” Into the Attorney-Client Privilege and Work Product Protection," a virtual program hosted by the Practising Law Institute (PLI).
August 17, 2026
Publications
Special Counsel Kimberly Cook Featured in FCBA Member Spotlight
The Federal Communications Bar Association (FCBA) featured Kimberly Cook in its Member Spotlight series.
August 13, 2026
Recognition
Three Jenner & Block Partners Named to Crain's New York Business' 2026 Notable Leaders in Accounting, Consulting & Law List
Crain's New York Business recognized Jenner & Block Partners Anthony Barkow, Alison Stein, and Damian Williams among its 2026 Notable Leaders in Accounting, Consulting & Law.
August 10, 2026
Publications
In Law360, Trump Debarment Threat Calls for Targeted Defense Plan
Partners Ashley Callen and David Robbins authored an article for Law360 examining how entities should respond when suspension or debarment is threatened directly by the president, rather than initiated through the usual agency-driven process.
August 6, 2026
Publications
"DC Circuit Undercuts Congress's Subpoena Power: Important New Authority for Targets of Congressional Investigations," National Law Journal
In the National Law Journal, Congressional Investigations Co-Chair Emily Loeb, Special Counsel David Manners-Weber, and Associate Kate Mather examine a recent DC Circuit decision that gives fresh weight to 2020 Supreme Court dicta on common-law privileges in congressional investigations.
July 30, 2026